News | April 30, 2023
Aarti Drugs reports Q4 FY23 PAT at Rs.56.02 Cr
Specialty Chemicals grew 38% YoY for FY23
Specialty Chemicals grew 38% YoY for FY23
This approval reflects Biocon Biologics' compliance with the highest international regulatory standards
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Cipla has recently signed an agreement to make and market the diabetes therapy Galvus and its combination brands in India from 01 January 2026.
The YP-P10 pre-clinical head-to-head study, jointly conducted by five people including Dr. Kyungho Park of Naason Science
The news on a shift in its focus comes after the refinement of Bayer’s early innovation framework
Company intends to increase sales in the UK to approximately 2 million Euros by focusing on seven molecules which are already registered in the country
Subscribe To Our Newsletter & Stay Updated
